San Diego – December 9, 2019 – Cooley advised clinical-stage biotechnology company Synthorx on its agreement to sell to Sanofi for approximately $2.5 billion. Partners Barbara Borden, Rama Padmanabhan and Ken Rollins led the Cooley team advising Synthorx.
Under the terms of the agreement, Sanofi will acquire all outstanding shares of Synthorx for $68 per share in cash. The transaction has been unanimously approved by both the Sanofi and Synthorx boards of directors and is expected to close in Q1 2020.
“We are grateful that Sanofi has acknowledged the value of our expanded genetic alphabet platform and the potential of our pipeline of optimized therapeutics for cancer and autoimmune disorders,” Laura Shawver, president and CEO of Synthorx, said in a statement.
Synthorx focuses on prolonging and improving the lives of people suffering from cancer and autoimmune disorders. The company’s proprietary, first-of-its-kind expanded genetic alphabet platform technology broadens the genetic code by adding a new DNA base pair. Alone and in combination with other existing Sanofi platforms, the technology will enable development of a range of novel biologics.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,000+ lawyers across 15 offices in the United States, Asia and Europe.